	US 11,684,678 B2
	Plasma-derived nanoparticles
Miguel Angelo Correia Dos Santos, Paddington (AU); Elysse Filipe, Paddington (AU); Praveesuda Lorwattanapongsa, Newtown (AU); Marcela Bilek, Southerland (AU); and Steven Garry Wise, Panania (AU)
Assigned to NANOMEDX, INC., Santa Clara, CA (US)
Appl. No. 16/471,180
Filed by THE HEART RESEARCH INSTITUTE LTD, Newtown (AU)
PCT Filed Dec. 21, 2017, PCT No. PCT/AU2017/051437 § 371(c)(1), (2) Date Jun. 19, 2019, PCT Pub. No. WO2018/112543, PCT Pub. Date Jun. 28, 2018.
Claims priority of application No. 2016905306 (AU), filed on Dec. 21, 2016.
Prior Publication US 2020/0023074 A1, Jan. 23, 2020
Int. Cl. A61K 47/69 (2017.01); A61K 47/62 (2017.01); A61K 47/68 (2017.01); A61K 9/16 (2006.01); A61K 49/00 (2006.01); C08F 138/02 (2006.01); C12N 15/113 (2010.01)

CPC A61K 47/6933 (2017.08) [A61K 9/1635 (2013.01); A61K 9/1676 (2013.01); A61K 9/1694 (2013.01); A61K 47/62 (2017.08); A61K 47/6835 (2017.08); A61K 49/0034 (2013.01); A61K 49/0093 (2013.01); C08F 138/02 (2013.01); C12N 15/1136 (2013.01)]

15 Claims

1. A conjugate comprising:

an aggregate comprising two or more nanoparticulate polymers having mean diameters of 1 nm to 50 nm, wherein the aggregate has a mean diameter of 5 nm to 500 nm, and wherein the nanoparticulate polymers are formed from a plasma comprising acetylene; and

at least one species selected from the group consisting of: a pharmaceutical drug, an imaging agent, a photosensitive dye, a cleavable linking molecule, and a hydrocarbon.